

Konstantinos Venetis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2473036/publications.pdf>

Version: 2024-02-01

36
papers

687
citations

516710

16
h-index

610901

24
g-index

36
all docs

36
docs citations

36
times ranked

421
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 801-810.	1.7	19
2	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 787-800.	1.7	25
3	Abstract P4-07-02: Tumor microenvironment characteristics and prognosis in breast cancer during pregnancy: The role of differentially expressed immune-related genes. <i>Cancer Research</i> , 2022, 82, P4-07-02-P4-07-02.	0.9	0
4	Abstract P3-18-08: Feasibility and safety of breast-conserving surgery in early-stage breast cancers during the first trimester of pregnancy. <i>Cancer Research</i> , 2022, 82, P3-18-08-P3-18-08.	0.9	0
5	Abstract P4-10-15: Whole-body vibration combined with physical exercise to treat aromatase inhibitor-induced musculoskeletal symptoms in breast cancer women: Results of a pilot randomized controlled study. <i>Cancer Research</i> , 2022, 82, P4-10-15-P4-10-15.	0.9	0
6	Abstract P4-10-23: Combined analysis of PTEN and routinely assessed biomarkers reveals new high-risk subgroups of HR- or HER2+ breast cancers. <i>Cancer Research</i> , 2022, 82, P4-10-23-P4-10-23.	0.9	0
7	Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years™ Single-Institution Experience of 762 Consecutive Patients. <i>Cancers</i> , 2022, 14, 1638.	3.7	3
8	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.	3.5	63
9	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605.	4.1	31
10	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103643.	4.4	25
11	Abstract PS9-36: Exercise therapy to reduce breast cancer fatigue: Results from the EXPECT study. , 2021, , .		0
12	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021, 145, 197-209.	2.8	16
13	Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities. <i>Journal of Molecular Pathology</i> , 2021, 2, 93-100.	1.2	10
14	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. <i>Cancer Cell International</i> , 2021, 21, 266.	4.1	26
15	Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. <i>Cells</i> , 2021, 10, 1377.	4.1	35
16	Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients. <i>Current Opinion in Pharmacology</i> , 2021, 58, 27-34.	3.5	8
17	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. <i>Frontiers in Oncology</i> , 2021, 11, 723693.	2.8	8
18	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. <i>Future Oncology</i> , 2021, 17, 4607-4618.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 735476.	2.8	2
20	Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. <i>BMC Cancer</i> , 2021, 21, 1152.	2.6	9
21	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 829875.	2.8	19
22	Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor-Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1369.	2.5	14
23	Metaplastic breast cancers and triple-negative breast cancers of no special type. <i>European Journal of Cancer Prevention</i> , 2021, Publish Ahead of Print, .	1.3	7
24	Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. <i>Histology and Histopathology</i> , 2021, , 18376.	0.7	11
25	Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. <i>Lung Cancer</i> , 2020, 150, 53-61.	2.0	36
26	Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers. <i>Translational Cancer Research</i> , 2020, 9, 4060-4064.	1.0	24
27	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 556718.	2.8	49
28	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. <i>Cancer Treatment Reviews</i> , 2020, 90, 102089.	7.7	27
29	Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. <i>Gastrointestinal Disorders</i> , 2020, 2, 341-352.	0.8	7
30	Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients' Quality of Life. <i>Current Osteoporosis Reports</i> , 2020, 18, 422-431.	3.6	20
31	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. <i>Genes</i> , 2020, 11, 719.	2.4	67
32	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1461.	4.1	25
33	Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema. <i>Frontiers in Oncology</i> , 2020, 10, 422.	2.8	17
34	Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. <i>Ecancermedicalscience</i> , 2020, 14, 1150.	1.1	27
35	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452.	4.1	53
36	Hereditary gastric and breast cancer syndromes with lung metastasis: narrative review of molecular and clinical insights. <i>AME Surgical Journal</i> , 0, .	0.0	0